Log in

OTCMKTS:CLIGFClinigen Group Stock Price, Forecast & News

$10.21
0.00 (0.00 %)
(As of 06/23/2020)
Add
Compare
Today's Range
$10.21
Now: $10.21
$10.21
50-Day Range
$8.75
MA: $10.01
$10.74
52-Week Range
$6.00
Now: $10.21
$12.30
Volume468 shs
Average Volume56 shs
Market Capitalization$1.25 billion
P/E Ratio14.80
Dividend YieldN/A
Beta0.69
Read More
Clinigen Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.80 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CLIGF
Previous SymbolNASDAQ:CLIGF
CUSIPN/A
CIKN/A
Phone44-12-8349-5010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$591.34 million
Cash Flow$1.19 per share
Book Value$4.68 per share

Profitability

Miscellaneous

Employees1,133
Market Cap$1.25 billion
Next Earnings Date9/16/2020 (Estimated)
OptionableNot Optionable

Receive CLIGF News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIGF and its competitors with MarketBeat's FREE daily newsletter.

Clinigen Group (OTCMKTS:CLIGF) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at $9.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLIGF stock has increased by 13.4% and is now trading at $10.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clinigen Group.

When is Clinigen Group's next earnings date?

Clinigen Group is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Clinigen Group.

Has Clinigen Group been receiving favorable news coverage?

News articles about CLIGF stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clinigen Group earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news about Clinigen Group.

Who are some of Clinigen Group's key competitors?

What is Clinigen Group's stock symbol?

Clinigen Group trades on the OTCMKTS under the ticker symbol "CLIGF."

How do I buy shares of Clinigen Group?

Shares of CLIGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clinigen Group's stock price today?

One share of CLIGF stock can currently be purchased for approximately $10.21.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of $1.25 billion and generates $591.34 million in revenue each year. The company earns $6.78 million in net income (profit) each year or $0.69 on an earnings per share basis. Clinigen Group employs 1,133 workers across the globe.

What is Clinigen Group's official website?

The official website for Clinigen Group is www.clinigengroup.com.

How can I contact Clinigen Group?

Clinigen Group's mailing address is PITCAIRN HOUSE CROWN SQUARE FIRST AVENUE, Burton-on-Trent X0, DE14 2WW. The company can be reached via phone at 44-12-8349-5010.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.